Centessa Pharmaceuticals plc — Director's Dealing 2021

Nov 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Centessa Pharmaceuticals plc (CNTA)
CIK: 0001847903
Period of Report: 2021-11-01

Reporting Person: GRAINGER DAVID J (Chief Innovation Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-01	Share Option (right to buy)	$14.01	A	175000	Acquired	2031-11-01	Ordinary Shares (175000)	Direct

Footnotes

F1: 25% of the shares subject to such option shall vest and become exercisable on November 1, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.

F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.